47045-COD-C-UNDP-1 The Global Fund to Fight AIDS, Tuberculosis and Malaria Congo (Democratic Republic), TB/HIV, United Nations Development Programme Goals: Contribuer à l'accéleration du progres vers la fin de l'épidemie de la TB en RDC / Contribute to accelerating progress towards the end of the TB epidemic in DRC; Faire de la RDC un pays avec « ZERO nouvelle infection, ZERO décès lié au VIH/Sida et ZERO discrimination et stigmatisation » dans la perspective qu’en RDC, le VIH ne soit plus un problème de santé Publique à l’horizon 2030. / To make the DRC a country with ZERO new infections, ZERO HIV/AIDS-related deaths, and ZERO discrimination and stigmatization so that by 2030, HIV will no longer be a public health problem in the DRC. Objectives: Dépister un total cumulé de 854 736 cas de TB toutes formes dans le cadre du GC7 parmi lequel 137 901 enfants et 6330 cas de TBMR / Screen a cumulative total of 854,736 cases of all forms of TB within the framework of GC7, including 137,901 children and 6,330 cases of MDR-TB; Traiter avec succès au moins 95% des patients TB PS notifiés et au moins 85 % des TB MR notifiés; / Successfully treat at least 95% of notified SP-TB patients and at least 85% of notified MDR-TB patients;; Mettre sous traitement d’infection latente enfants de moins de 5 ans en contact avec des cas TB+ exclue de la TB (352 801) ; / Put on treatment for latent infection children under 5 years of age in contact with TB+ cases excluded from TB (352,801);; Tester au VIH au moins 90% des patients tuberculeux notifiés durant la période ; / Test at least 90% of TB patients notified during the period for HIV;; Mettre sous ARV 95% des patients coïnfectés (TB VIH+) durant la période dans le pays ; / Put 95% of co-infected patients (HIV+ TB) on ARVs during the period in the country;; Réduire les nouvelles infections VIH de 95% d’ici 2027 / Reduce new HIV infections by 95% by 2027; Réduire les nouvelles infections chez les nourrissons nés des mères infectées par le VIH de 98 % d'ici 2027 / Reduce new infections among infants born to HIV-infected mothers by 98% by 2027; Réduire la mortalité liée au VIH de 9.5% à 7.4% / Reduce HIV-related mortality from 9.5% to 7.4% by the end of 2027; Reduire la discrimination, la stigmatisation et les inégalités sociales liées au VIH/TB à l’égard des PVVIH, populations clés (Transgenre, HSH, PS, UDI, PS, détenus ) et autres populations vulnérables (SVS, SVBG et OEV) de 95% d’ici fin 2027 / Reduce discrimination, stigma and social inequalities related to HIV/TB for PLHIV, key populations (Transgender, MSM, PS, IDU, PS, prisoners) and other vulnerable populations (SVS, SVBG and OVC) by 95% by the end of 2027; Soutenir la riposte nationale VIH par une bonne gouvernance et une coordination multisectorielle optimale à tous les niveaux d’ici à 2027 / Support the national HIV response through good governance and optimal multisectoral coordination at all levels by 2027. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria Communications +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS, Tuberculosis and Malaria Grant Management Division Sonia Florisse Fund Portfolio Manager +41 58 791 1700 sonia.florisse@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Congo (Democratic Republic) HIV Tuberculosis Multicomponent, RSSH Ensure healthy lives and promote well-being for all at all ages End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases Achieve universal health coverage HIV -> Differentiated HIV Testing Services -> Community-based testing for AGYW and their male sexual partners programs HIV -> Differentiated HIV Testing Services -> Community-based testing for KP programs HIV -> Differentiated HIV Testing Services -> Community-based testing outside of KP and AGYW programs HIV -> Differentiated HIV Testing Services -> Facility-based testing for adolescent girls and young women (AGYW) and their male sexual partners programs HIV -> Differentiated HIV Testing Services -> Facility-based testing for key population (KP) programs HIV -> Differentiated HIV Testing Services -> Facility-based testing outside of key population (KP) and adolescent girls and young women (AGYW) programs HIV -> Differentiated HIV Testing Services -> Self-testing for AGYW and their male sexual partners programs HIV -> Differentiated HIV Testing Services -> Self-testing for KP programs HIV -> Differentiated HIV Testing Services -> Self-testing outside of KP and AGYW programs HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Early infant diagnosis and follow-up HIV testing for exposed infants HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Integrated testing of pregnant women for HIV, syphilis and hepatitis B HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Post-natal infant prophylaxis HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Condom and lubricant programming for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Pre-exposure prophylaxis (PrEP) programming for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for MSM HIV -> Prevention package for other vulnerable populations (OVP) -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for OVP HIV -> Prevention package for people in prisons and other closed settings -> Condom and lubricant programming for prisoners HIV -> Prevention package for people in prisons and other closed settings -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for prisoners HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Condom and lubricant programming for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> HIV prevention communication, information and demand creation for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Needle and syringe programs for PWID HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Opioid substitution therapy and other medically assisted drug dependence treatment for PWID HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Overdose prevention and management for PWID HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Pre-exposure prophylaxis (PrEP) programming for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for PUD HIV -> Prevention package for sex workers, their clients and other sexual partners -> Condom and lubricant programming for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> HIV prevention communication, information and demand creation for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> Pre-exposure prophylaxis (PrEP) programming for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for sex workers HIV -> Prevention package for transgender people and their sexual partners -> Condom and lubricant programming for transgender people HIV -> Prevention package for transgender people and their sexual partners -> HIV prevention communication, information and demand creation for transgender people HIV -> Prevention package for transgender people and their sexual partners -> Pre-exposure prophylaxis (PrEP) programming for transgender people HIV -> Prevention package for transgender people and their sexual partners -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for transgender people HIV -> Prevention program stewardship -> Prevention program stewardship HIV -> Reducing human rights-related barriers to HIV/TB services -> Ensuring nondiscriminatory provision of health care HIV -> Treatment, care and support -> Diagnosis and management of advanced HIV disease (adults and children) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - adults (15 and above) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - children (under 15) HIV -> Treatment, care and support -> Integrated management of common co-infections and co-morbidities (adults and children) HIV -> Treatment, care and support -> Treatment monitoring - Viral load and antiretroviral (ARV) toxicity Multicomponent -> Program management -> Grant management RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: Biosafety and biosecurity, infrastructure and equipment RSSH -> RSSH: Community systems strengthening -> Capacity building and leadership development RSSH -> RSSH: Health products management systems -> Planning and procurement capacity RSSH -> RSSH: Monitoring and evaluation systems -> Analyses, evaluations, reviews and data use RSSH -> RSSH: Monitoring and evaluation systems -> Data quality RSSH -> RSSH: Monitoring and evaluation systems -> Routine reporting Tuberculosis -> Collaboration with other providers and sectors -> Community-based TB/DR-TB care Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB diagnosis/drug susceptibility testing (DST) Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB treatment, care and support Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Children and adolescents Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Miners and mining communities Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - People in prisons/jails/detention centers Tuberculosis -> Removing human rights and gender related barriers to TB services -> Eliminating TB-related stigma and discrimination Tuberculosis -> TB diagnosis, treatment and care -> TB screening and diagnosis Tuberculosis -> TB diagnosis, treatment and care -> TB treatment, care and support Tuberculosis -> TB/DR-TB Prevention -> Infection prevention and control (IPC) Tuberculosis -> TB/HIV -> TB/HIV - Prevention Tuberculosis -> TB/HIV -> TB/HIV - Screening, testing and diagnosis Tuberculosis -> TB/HIV -> TB/HIV - Treatment and care 1571338.51 73807884.44 64664619.95 42828746.00 Global Fund commitment to COD-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 42828746.00 Global Fund disbursement to COD-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 101894342.00 Global Fund commitment to COD-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5951605.00 Global Fund disbursement to COD-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 59650035.00 Global Fund disbursement to COD-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -36292702.00 Global Fund commitment to COD-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 0.00 Global Fund commitment to COD-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 21191461.00 Global Fund commitment to COD-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3183497.00 Global Fund disbursement to COD-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 14717018.57 Global Fund disbursement to COD-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 13712941.00 Global Fund commitment to COD-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -3290945.43 Global Fund commitment to COD-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 9255657.00 Global Fund disbursement to COD-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2177502.04 Global Fund disbursement to COD-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 1571338.51 Expenditure reported by United Nations Development Programme for COD-C-UNDPP01, Oct 2024 to Dec 2024. United Nations Development Programme 58573215.77 Expenditure reported by United Nations Development Programme for COD-C-UNDPP01, Jan 2025 to Dec 2025. United Nations Development Programme An overview of a grant over its lifetime. General terms and conditions which apply to Global Fund grants. Funding Request of funding request FR1493-COD-C. Funding Request of funding request FR1493-COD-C. 1 - To the extent consistent with and without prejudice to the Framework Agreement and, in particular, Article 2 of the UNDP-Global Fund Grant Regulations, the Principal Recipient shall be guided by the Global Fund Guidelines for Grant Budgeting (2023, as amended from time to time, available at the Global Fund’s Internet site) in the budgeting of the Grant. 2 - Personal Data (1) Principles. Program Activities are expected to respect the following principles and rights (“Data Protection Principles”): (a) Information that could be used to identify a natural person (“Personal Data”) will be: (i) processed lawfully, fairly and transparently; (ii) collected for specified, explicit and legitimate purposes and not further processed in a manner not compatible with those purposes;  (iii) adequate, relevant and limited to what is necessary for the purposes for which they are processed; (iv) accurate and, where necessary, kept up to date; (v) kept in a form which permits identification of the individuals for no longer than is necessary for the purposes for which the Personal Data is processed; and (vi) processed in a manner that ensures appropriate security of the Personal Data; and (b) Natural persons are afforded, where relevant, the right to information about Personal Data that is processed; the right to access and rectify or erase Personal Data; the right to data portability; the right to confidentiality of electronic communications; and the right to object to processing. (2) Limitations. Where collection and processing of Personal Data is required in order to implement Program Activities, whether by the Principal Recipient, a Sub-recipient, or Supplier, the Principal Recipient should respect the Data Protection Principles: (a) to the extent that doing so does not violate or conflict with any law and/or policy applicable to it; and (b) subject to the Principal Recipient balancing the Data Protection Principles with other fundamental rights in accordance with the principle of proportionality, taking into account the risks to the rights and freedoms of natural persons. (3) The Global Fund may collect or seek to collect data, and it is possible that such data may contain Personal Data. Prior to collection and at all times thereafter, the Principal Recipient shall take all necessary actions to ensure that the transfer of such information to the Global Fund does not violate any law or regulation applicable to the Principal Recipient. 3 - The Principal Recipient shall take all appropriate and necessary actions to ensure that it and any Sub-recipient complies with the “Asset Guidelines for Global Fund Grant Transitions” dated 2 June 2023 (as amended from time to time), the provisions of which are incorporated by reference into the Grant Agreement. 4 - (1)  In accordance with the Global Fund’s Sustainability, Transition and Co-financing Policy (GF/B35/04) (the “STC Policy”), the commitment and disbursement of USD 53,641,831. (the “Co-Financing Incentive”), is subject to the Global Fund’s satisfaction with the Host Country’s compliance with the requirements listed at 4.4(1)(a) and 4.4(1)(b) below (“Co-Financing Requirements”). The Principal Recipient acknowledges and agrees that the Global Fund may reduce Grant Funds during the current or any subsequent Implementation Period in the event the Host Country fails to: (a) progressively increase government expenditure on health to meet national universal health coverage goals; and/or (b) increase domestic funding of Global Fund-supported programs, with a focus on progressively absorbing the key costs of national disease plans, as identified in consultation with the Global Fund. (2) In order to satisfy the Co-Financing Requirements, the Principal Recipient acknowledges and agrees that the Host Country shall, as set out in the co-financing commitment letter of the Host Country government and annex tables, dated 17 October 2023 and 23 November 2023 (the “Commitment Letter”), unless otherwise agreed in writing by the Global Fund: (a) fulfil a total minimum co-financing commitment of USD 128,700,773 from 2024-2026 (inclusive), comprising investments in: (i) HIV of USD 8,310,000 for the purchase of essential commodities; (ii) TB of USD 2,595,000 for the purchase of essential commodities; and (iii) RSSH of USD 117,795,773. (b) fulfil the programmatic commitments as stipulated in Annex 1 of the Commitment Letter; and (c) provide to the Global Fund, by no later than 31 March of each year of the Implementation Period and the year following the end of the Implementation Period, evidence supporting achievement of the Co-Financing Requirements, including: (i) the approved annual budget for specific HIV / TB and RSSH budget lines for the upcoming year; and (ii) the total expenditure for specific HIV / TB and RSSH budget lines in the previous fiscal year. 5 - Unless otherwise notified by the Global Fund in writing, prior to the use of Grant Funds to finance the procurement of second-line anti-tuberculosis drugs and for each disbursement request that includes funds for the procurement of multi-drug resistant tuberculosis medicines, the Principal Recipient shall submit to the Global Fund and obtain the Global Fund’s written approval of a written confirmation of the price estimate and quantities of the second-line anti-tuberculosis drugs that will be procured by the Principal Recipient from the Global Drug Facility’s procurement agent. Module: Differentiated HIV Testing Services. Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - other. Numerator: 4942; Denominator: 81791. Numerator: 1853; Denominator: 124784. Numerator: 2881; Denominator: 124784. Numerator: 20344; Denominator: 128404. Numerator: 29792; Denominator: 128404. Numerator: 9591; Denominator: 128404. Numerator: 20344; Denominator: 128404. Numerator: 29792; Denominator: 128404. Numerator: 25139; Denominator: 132127. Numerator: 29063; Denominator: 132127. Module: Differentiated HIV Testing Services. Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - other. Numerator: 2154; Denominator: 64672. Numerator: 808; Denominator: 110789. Numerator: 1462; Denominator: 110789. Numerator: 3952; Denominator: 114002. Numerator: 8214; Denominator: 114002. Numerator: 12826; Denominator: 114002. Numerator: 8214; Denominator: 114002. Numerator: 12826; Denominator: 114002. Numerator: 10150; Denominator: 117308. Module: Differentiated HIV Testing Services. Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - other. Numerator: 9550; Denominator: 146462. Numerator: 3581; Denominator: 316993. Numerator: 6444; Denominator: 316993. Numerator: 22655; Denominator: 326184. Numerator: 51085; Denominator: 326184. Numerator: 56273; Denominator: 326184. Numerator: 51085; Denominator: 326184. Numerator: 56273; Denominator: 326184. Numerator: 63127; Denominator: 335645. Numerator: 72979; Denominator: 335645. Module: Drug-resistant (DR)-TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 1125; Denominator: 1236; Percentage: 91.02%. Numerator: 1336; Denominator: 1403; Percentage: 95.22%. Numerator: 1336; Denominator: 1403; Percentage: 95.22%. Numerator: 67; Denominator: 1403; Percentage: 4.78%. Numerator: 67; Denominator: 1403; Percentage: 4.78%. Numerator: 540; Denominator: 1403; Percentage: 38.49%. Numerator: 540; Denominator: 1403; Percentage: 38.49%. Numerator: 0; Denominator: 1403; Percentage: 0%. Numerator: 0; Denominator: 1403; Percentage: 0%. Numerator: 863; Denominator: 1403; Percentage: 61.51%. Numerator: 863; Denominator: 1403; Percentage: 61.51%. Numerator: 1403; Denominator: 1403; Percentage: 100%. Numerator: 1403; Denominator: 1403; Percentage: 100%. Numerator: 1242; Denominator: 1242; Percentage: 100%. Numerator: 449; Denominator: 560; Percentage: 80.18%. Numerator: 432; Denominator: 449; Percentage: 96.21%. Numerator: 17; Denominator: 449; Percentage: 3.79%. Numerator: 190; Denominator: 449; Percentage: 42.32%. Numerator: 5. Numerator: 259; Denominator: 449; Percentage: 57.68%. Numerator: 444. Numerator: 1593; Denominator: 1593; Percentage: 100%. Numerator: 3186; Denominator: 3186; Percentage: 100%. Numerator: 1237; Denominator: 1384; Percentage: 89.38%. Numerator: 1593; Denominator: 1593; Percentage: 100%. Numerator: 554; Denominator: 632; Percentage: 87.66%. Numerator: 1188; Denominator: 1330; Percentage: 89.32%. Numerator: 49; Denominator: 154; Percentage: 31.82%. Numerator: 417; Denominator: 1237; Percentage: 33.71%. Numerator: 0. Numerator: 820; Denominator: 1237; Percentage: 66.29%. Numerator: 1237. Numerator: 2032; Denominator: 2032; Percentage: 100%. Numerator: 2032; Denominator: 2032; Percentage: 100%. Module: Drug-resistant (DR)-TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 1056; Denominator: 1242. Numerator: 1174; Denominator: 1415. Numerator: 2708; Denominator: 3186. Numerator: 1836; Denominator: 2099. Numerator: 1354; Denominator: 1593. Numerator: 1354; Denominator: 1593. Numerator: 840; Denominator: 993. Numerator: 1727; Denominator: 2032. Numerator: 1727; Denominator: 2032. Module: Prevention package for men who have sex with men (MSM) and their sexual partners. Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative. Module: Prevention package for men who have sex with men (MSM) and their sexual partners. Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - other. Numerator: 5101; Denominator: 81791. Numerator: 1913; Denominator: 124784. Numerator: 3053; Denominator: 124784. Numerator: 20973; Denominator: 128404. Numerator: 28390; Denominator: 128404. Numerator: 9891; Denominator: 128404. Numerator: 20973; Denominator: 128404. Numerator: 28390; Denominator: 128404. Numerator: 25917; Denominator: 132127. Numerator: 29962; Denominator: 132127. Module: Prevention package for people who use drugs (PUD) and their sexual partners. Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - other. Numerator: 2210; Denominator: 64672. Numerator: 829; Denominator: 110789. Numerator: 1500; Denominator: 110789. Numerator: 8214; Denominator: 114002. Numerator: 9404; Denominator: 114002. Numerator: 3980; Denominator: 114002. Numerator: 8214; Denominator: 114002. Numerator: 9404; Denominator: 114002. Numerator: 10150; Denominator: 117308. Numerator: 11734; Denominator: 117308. Module: Prevention package for sex workers, their clients and other sexual partners. Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative. Module: Prevention package for sex workers, their clients and other sexual partners. Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - other. Numerator: 9808; Denominator: 146462. Numerator: 3678; Denominator: 316993. Numerator: 6759; Denominator: 316993. Numerator: 51601; Denominator: 326184. Numerator: 66065; Denominator: 326184. Numerator: 22964; Denominator: 326184. Numerator: 51601; Denominator: 326184. Numerator: 66065; Denominator: 326184. Numerator: 63764; Denominator: 335645. Numerator: 73716; Denominator: 335645. Module: RSSH: Health products management systems. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 1976; Denominator: 2116. Numerator: 1289; Denominator: 2361. Numerator: 1665; Denominator: 2395. Numerator: 1665; Denominator: 2395. Module: RSSH: Health products management systems. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 3699; Denominator: 4044. Numerator: 1864; Denominator: 4076. Numerator: 4184; Denominator: 4750. Numerator: 4184; Denominator: 4750. Module: RSSH: Health products management systems. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 3211; Denominator: 3931. Numerator: 1421; Denominator: 4162. Numerator: 1412; Denominator: 2395. Numerator: 1412; Denominator: 2395. Module: TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 81154; Denominator: 253423. Numerator: 16563; Denominator: 69868. Numerator: 86754; Denominator: 280484. Numerator: 52699; Denominator: 141098.